Introduction to Advacan-0.5 Tablets
Advacan-0.5 Tablet contains the active substance Everolimus. It belongs to a group of medicines known as immunosuppressants, specifically acting as a selective mTOR (mammalian target of rapamycin) inhibitor. In this formulation, it is primarily indicated for the prophylaxis of organ rejection in adult patients receiving an allogeneic kidney or liver transplant. It is typically used in immediate combination with a cyclosporine microemulsion and corticosteroids to provide a multi-targeted immunosuppressive drug regimen.
Everolimus works by binding to an intracellular protein (FKBP-12), and this complex subsequently blocks the activation of the mTOR kinase. Because mTOR is a central regulator of cell translation, growth, and survival, inhibiting it prevents T-lymphocytes from multiplying and responding to interleukin-2 (IL-2) signals. By shutting down this critical arm of the immune system, Advacan-0.5 prevents your body's immune cells from recognizing and attacking the newly transplanted organ, ensuring long-term graft survival.
Advacan-0.5 Tablets must be used under the strict, regular supervision of a transplant specialist, nephrologist, or hepatologist. The dosage must be carefully monitored, and routine blood tests are mandatory to measure the exact trough levels of the drug in your system to prevent under-dosing (rejection) or over-dosing (toxicity).
Before starting treatment, inform your healthcare professional if you have a history of high cholesterol or triglycerides, liver impairment, severe respiratory conditions, diabetes, or an active infection. Seek immediate emergency medical care if you develop unexpected respiratory symptoms (such as a sudden cough or breathing difficulties), a high fever, signs of a localized infection, or delayed healing of your surgical wound site.
Uses of Advacan-0.5 Tablets
Uses of Advacan-0.5 Tablets:
-
Prevention of organ rejection in adult patients undergoing an allogeneic kidney transplant.
-
Prevention of organ rejection in adult patients undergoing an allogeneic liver transplant.
-
Preservation of long-term graft function when used in combination therapy following organ transplantation.
Therapeutic Effects of Advacan-0.5 Tablets
Advacan-0.5 Tablets exert their therapeutic effect by putting a strategic brake on your body's immune responses. By directly blocking the mTOR cellular signaling pathway, the drug prevents lymphocyte proliferation from passing from the G1 phase into the S phase of cell division. This selective suppression lowers the counts and activities of specific white blood cells that would otherwise target the tissue antigens of the transplanted organ. Consequently, it establishes immune tolerance, minimizes the risk of sudden acute rejection episodes, and preserves the functional integrity of the graft.
Interaction of Advacan-0.5 Tablets with other drugs
It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Advacan-0.5 Tablets, potentially affecting their effectiveness or causing serious side effects. Notable interactions include:
-
Strong CYP3A4 and P-gp Inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin): These can dramatically increase the levels of Everolimus in your blood, increasing the risk of dangerous side effects.
-
Strong CYP3A4 and P-gp Inducers (Rifampicin, Phenytoin, Carbamazepine, St. John's Wort): These can heavily lower Everolimus levels, potentially causing the medicine to fail and increasing the risk of organ rejection.
-
Cyclosporine: Co-administration increases the absorption of Everolimus. Your doctor will carefully adjust the doses of both drugs when used together.
-
Live Vaccines: You must avoid all live vaccines during treatment, as the drug suppresses your immune defenses and elevates the risk of vaccine-derived infections.
More Information about Advacan-0.5 Tablets
-
Keep out of reach of children and pets.
-
Store in a dry place at a temperature not exceeding 25°C.
-
Keep the tablets stored in their original blister pack inside the outer carton box to protect the medication from light and moisture.
How to consume Advacan-0.5 Tablets
Advacan-0.5 Tablets are oral medications meant to be swallowed whole with a glass of water. Do not crush, chew, or split the tablets. Take your dose exactly as directed by your transplant team. You must take this medication consistently either always with food or always on an empty stomach to keep blood levels stable. Never switch your routine from day to day. Avoid consuming grapefruit, grapefruit juice, or Seville oranges while taking Advacan-0.5, as they interfere with the enzymes that break down the drug, leading to toxic levels in your body.
Safety Advice for Advacan-0.5 Tablets
Breast Feeding
Unsafe It is unknown if Everolimus passes into human breast milk. However, due to the high risk of serious cellular side effects and immunosuppression in the infant, breastfeeding is contraindicated during treatment and for 2 weeks after the final dose.
Alcohol
Caution Minimize or avoid alcohol consumption while taking Advacan-0.5. Alcohol can complicate liver metabolism panels and aggravate secondary side effects like headaches or dizziness.
Liver
Caution Everolimus is heavily processed by the liver. Patients with baseline mild-to-moderate hepatic impairment require careful dose adjustments and intensive monitoring of Everolimus blood trough concentrations. It is generally not recommended for severe liver disease.
Lungs
High Caution Everolimus can cause non-infectious pneumonitis (inflammation of the lung tissue), which can be severe or life-threatening. Inform your physician immediately if you develop any new or worsening respiratory symptoms, such as a dry cough or shortness of breath.
Driving
Safe Advacan-0.5 Tablets do not typically affect your ability to drive or operate heavy machinery. However, if you experience unexpected fatigue or dizziness, avoid driving until you feel completely alert.
Pregnancy
Unsafe This medication can cause serious fetal harm and development issues when given to a pregnant woman. Women of childbearing potential must use highly effective, reliable methods of contraception during treatment and for up to 8 weeks after stopping the medication.
Side Effects of Advacan-0.5 Tablets
Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.
Common side effects of Advacan-0.5 Tablets are:
-
Mouth ulcers or painful sores in the mouth
-
Increased blood lipid levels (high cholesterol and triglycerides)
-
Swelling of limbs or face (peripheral edema)
-
High blood pressure (hypertension)
-
Increased susceptibility to urinary tract or upper respiratory infections
-
Nausea, diarrhea, or mild abdominal pain
Serious side effects of Advacan-0.5 Tablets are:
-
Non-infectious Pneumonitis: (Persistent dry cough, severe chest tightness, sudden shortness of breath).
-
Severe Infections: (High fever, severe chills, fatigue, signs of localized wound infections due to profound immunosuppression).
-
Angioedema: (Sudden swelling of the face, lips, tongue, or throat causing severe swallowing or breathing difficulties).
-
New or Worsening Kidney Issues: (Decreased urine output, sudden fluid accumulation).
Word of Advice
Never miss a scheduled laboratory appointment for your Therapeutic Drug Monitoring (TDM) blood tests, as measuring your Everolimus blood concentration levels is the only definitive way your doctor can keep your transplanted organ safe while avoiding systemic drug toxicities. Because this medicine lowers your body's immune defenses, practice excellent personal hygiene, avoid close contact with individuals who have active contagious viral or bacterial illnesses, and wear protective clothing outdoors to minimize the risk of skin damage or infection.
FAQs about Advacan-0.5 Tablets
Q1. What is Therapeutic Drug Monitoring (TDM) and why is it necessary for Advacan-0.5? Everolimus has a narrow therapeutic window, meaning that if the drug level in your blood falls too low, your immune system may reject your new organ, but if it climbs too high, it can cause severe toxicity to your kidneys and liver. Regular blood tests allow your doctor to find the precise sweet spot and adjust your daily tablet counts accordingly.
Q2. Why can't I take my Advacan-0.5 tablet with food on some days and without food on other days? Food changes the rate and extent to which Everolimus is absorbed into your bloodstream. If you switch back and forth between taking it with meals and on an empty stomach, your blood levels will fluctuate unpredictably. To keep your levels stable and your transplant safe, choose one method and stick to it strictly.
Q3. Can I drink grapefruit juice while taking Advacan-0.5 Tablets? No, you must completely avoid grapefruit, grapefruit juice, and products containing Seville oranges. They contain compounds that inhibit the CYP3A4 enzyme in your gut, which is responsible for breaking down Everolimus. This blockage can cause a sudden, dangerous spike in the medicine's concentration in your blood.
Q4. What should I do if I develop painful mouth ulcers while taking this medicine? Mouth sores (stomatitis) are a very common side effect of mTOR inhibitors like Advacan. Avoid eating spicy, acidic, or very crunchy foods that can irritate your mouth. Your transplant team can prescribe special, alcohol-free therapeutic mouthwashes or topical gels to relieve pain and help the sores heal.
Q5. How long do I need to keep taking Advacan-0.5 Tablets after my transplant surgery? Immunosuppressive therapy following an organ transplant is typically a lifelong requirement to prevent graft rejection. Never stop taking your medication, skip a dose, or alter your schedule without explicit orders from your transplant specialist.
Fact Box of Advacan-0.5 Tablets
-
Molecule name: Everolimus (0.5mg)
-
Therapeutic class: Immunossuppressants
-
Pharmacological class: mTOR Inhibitors (Proliferation Signal Inhibitors)
-
Indications: 1. Prophylaxis of organ rejection in adult patients receiving an allogeneic kidney transplant. 2. Prophylaxis of organ rejection in adult patients receiving an allogeneic liver transplant.
References
-
Tedesco-Silva H, et al. Everolimus early introduction and cyclosporine minimization in kidney transplantation. https://pubmed.ncbi.nlm.nih.gov/26107153/
-
Eisen HJ, et al. Everolimus for the prevention of allograft rejection in cardiac transplant recipients. https://pubmed.ncbi.nlm.nih.gov/14602879/
-
Organ Transplantation Medical Evaluation Group. National Guidelines on Immunosuppressive Therapy Management. [Updated 2026]. Available from: https://clinicalinfo.org/
-
Food and Drug Administration (FDA). Zortress (Everolimus) Oral Tablets Prescribing Information & Blood Trough Tracking Protocols. https://www.accessdata.fda.gov/
Disclaimer
Medipoint India’s primary intention is to ensure that its consumers get accurate, trustworthy, and expert-reviewed information. The contents of this website are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Medipoint India. Our mission is to support, not replace, the doctor-patient relationship.
